Immutep (ASX:IMM) Receives Japanese Patent for LAG525 – The Market Herald
- Biotechnology company Immutep (IMM) receives patent from Japan Patent Office for LAG525
- The patent is titled “antibody molecules against LAG-3 and uses thereof” and will expire on March 13, 2035
- LAG525 is a humanized form of Immutep’s IMP701 antibody that was developed to target LAG-3 – cell surface molecules with diverse biological effects on T cell function
- It works by blocking T cells from obstructing inhibitory signals that would otherwise turn them off and prevent them from locating a foreign object
- Immutep ends the day in the green with shares trading at 39.5 cents
Biotechnology company Immutep (IMM) has received a patent from the Japanese Patent Office for LAG525.
The patent is titled “antibody molecules against LAG-3 and uses thereof” and will expire on March 13, 2035.
The patent was filed as a divisional application and follows the issuance of the parent Japanese patent announced in 2019.
Similar patents have been granted in other countries such as Australia, Europe, China and the United States.
LAG525 is a humanized form of Immutep’s IMP701 antibody which was developed to target LAG-3 (Lymphocyte Activation Gene-3) – cell surface molecules with various biological effects on T cell function.
It works by blocking T cells, a part of the immune system that focuses on specific foreign particles, from obstructing inhibitory signals that would otherwise turn them off and prevent them from locating foreign bodies.
Therefore, IMP701 removes two brakes that prevent the immune system from killing cancer cells.
LAG525 is currently being evaluated in Phase I and II clinical trials for the treatment of cancer.
Immutep ended the day 6.76% in the green with shares trading at 39.5 cents.
